Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27769165 | 0.79 | HTR6 (0.34) | HTR2CHTR2BHTR6PNMT | |
| SCHEMBL3093803 | 0.76 | SMN1; SMN2 (0.37) | SMN1; SMN2NLRP3HTR2CHTR2BHTR6 | |
| SCHEMBL3097281 | 0.75 | HTR6 (0.43) | SMN1; SMN2LMNAMAPTHTR6 | |
| SCHEMBL3092172 | 0.73 | NQO2 (0.48) | SMN1; SMN2MAPTHTR6 | |
| SCHEMBL3092580 | 0.71 | CA2 (0.50) | MAPTHTR6 | |
| SCHEMBL3088528 | 0.71 | NQO2 (0.51) | MAPT | |
| SCHEMBL315964 | 0.71 | HTR6 (0.70) | HTR6 | |
| SCHEMBL315799 | 0.71 | HTR6 (0.52) | HTR1AHTR2CHTR2BHTR6 | |
| SCHEMBL3080680 | 0.71 | HTR6 (0.49) | SMN1; SMN2MAPTHTR6 | |
| SCHEMBL3086379 | 0.71 | CA2 (0.49) | MAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| CN-101472885-A | Arylsulfonyl naphthalene derivatives and uses thereof | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-2041079-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147763-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147763-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ARSA, AR, SULT2A1 | SMN1; SMN2 662/4885NLRP3 3562/4885LMNA 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.